Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblastoma and other solid tumors - CLEE011Q12101

ovartis Pharma AG0 个研究点目标入组 91 人开始时间: 2024年3月14日最近更新: 2024年7月22日

试验速览

阶段: 1 期
状态: 招募中
发起方: ovartis Pharma AG
入组人数: 91

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 0 至 64（—）
性别: All

入选标准

•Signed informed consent/assent must be obtained prior to participation in the study. Participants and/or guardian must have the ability to understand and the willingness to sign a written informed consent document., Age = 12 months and = 21 years at the time of signing consent form., Histologically or cytologically confirmed solid tumors listed below that have progressed despite standard therapy or for which no effective standard therapy exists. a. Neuroblastoma (NB) (Phase I and Phase II) b. Medulloblastoma (MB) (Phase I) regardless of genetic status (i.e. Groups 3 or 4 WNT-activated or non-WNT, SHH-activated or non-SHH). c. High-grade glioma (HGG) (Phase I): Note: excluding any low grades (grade I or grade II) such as astrocytoma, oligodendroglioma, or mixed glioneuronal tumors d. Malignant rhabdoid tumor (MRT) (Phase I): includes diagnoses of atypical teratoid/rhabdoid tumor (AT/RT), and rhabdoid tumor of the kidney (RTK), and other soft tissues as defined by 2 of the 3 following criteria; either (i)+(ii) or (i)+(iii): e. Rhabdomyosarcoma (RMS) (Phase I) independent of fusion status and subtype., Participants with central nervous system (CNS) disease who are on corticosteroids should take stable doses for at least 7 days prior to first dose of ribociclib with no plans for escalation. Note: participants with symptomatic CNS disease who are neurologically unstable or require local CNS-directed therapy to control their CNS disease are not eligible for the study, Measurable disease per Revised Assessment in Neuro-Oncology (RANO) criteria for participants with HGG and per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for MB, MRT and RMS., Performance status: participants who are unable to walk because of paralysis, but who are able to sit upright unassisted in a wheelchair, will be considered ambulatory for the purpose of assessing performance score, Life expectancy of = 12 weeks at the time of enrollment., Adequate bone marrow function (bone marrow may be involved with tumor) and organ function defined as: a. Peripheral absolute neutrophil count (ANC) = 1000/mm3 without growth factor support within 7 days of the test b. Platelet count = 75,000/mm3 without support within 7 days of the test c. Hemoglobin = 8.0 g/dL (transfusion allowed) d. Total bilirubin = 1.5 x ULN for age (in case of Gilbert's syndrome, = 3.0 x ULN or direct bilirubin = 1.5 x ULN for age) e. Adequate liver function, defined as total serum bilirubin = 1.5 x ULN AND alanine aminotransferase (ALT) / aspartate aminotransferase (AST) = 2.5 x ULN (in case of liver metastases, AST / ALT = 5 x ULN) f. Adequate renal function, defined as serum creatinine = 1.5 x ULN based on age/gender normal. In participants with serum creatinine > 1.5 x ULN for age/gender normal, a calculated glomerular filtration rate (GFR) must be = 60 mL/min/1.73 m2. g. Adequate cardiac function, defined as corrected QTc interval using Fridericia's correction (QTcF) = 450 ms and shortening fraction (SF) > 29% (> 35% for participants < 3 years) and left ventricular ejection fraction (LVEF) = 50% on echocardiogram h. The following laboratory values within normal limits or corrected to within normal limits with supplements before first dose of study medication: Potassium; Magnesium; Total calcium (corrected for serum albumin)

排除标准

•Known hypersensitivity to any of the excipients of ribociclib or topotecan or temozolomide., Participated in a investigational study within 30 days or 5 half-lives, Received prior treatment with a CDK4/6 inhibitor, Received anticancer therapy (including experimental) within 4 weeks, Received myeloablative therapy with autologous hematopoietic stem cell rescue within 8 weeks, Received allogeneic stem cell transplant within 3 months, Has radiation within 4 weeks (or 2 weeks if radiation therapy is given for palliation), or within 6 weeks of MIBG treatment, Major surgery within 2 weeks and not recovered fully from the side effects, Not recovered from clinical and laboratory acute toxicities related to prior anti-cancer therapies, Concurrent severe and/or uncontrolled concurrent medical conditions that in the Investigator's judgement could compromise their ability to tolerate or absorb protocol therapy or would interfere with the study procedures or results, Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality, History of QTcF prolongation (i.e. QTcF interval of > 450 ms) or QTcF > 450 ms on screening ECG, Currently taking medications with a known risk to prolong the QT interval or induce TdP that cannot be discontinued or replaced by safe alternative medication, Currently taking medications that are known strong inducers or inhibitors of CYP3A4/5 cannot be discontinued at least 7 days or 5 halflives, Currently taking medications that are mainly metabolized by CYP3A4/5 with a narrow therapeutic index that cannot be discontinued at least 7 days or 5 half-lives, Vaccinated with live, attenuated vaccines within 4 weeks

研究者

发起方

ovartis Pharma AG

相似试验

进行中（未招募）

1 期

Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma) in patients from 12 months to 21 years oldMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10029261Term: Neuroblastoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2021-005617-14-DKovartis Pharma AG230

进行中（未招募）

1 期

EUCTR2021-005617-14-CZovartis Pharma AG230

进行中（未招募）

1 期

EUCTR2021-005617-14-DEovartis Pharma AG230

招募中

1 期

Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assessefficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)Relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma) in patients from 12 months to 21 years oldMedDRA version: 21.0Level: PTClassification code 10066595Term: Neuroblastoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10027107Term: MedulloblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10039024Term: Rhabdomyosarcoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2021-005617-14-ITOVARTIS PHARMA AG230

已完成

2 期

Multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancercolorectal cancer

JPRN-UMIN000027887ational Cancer Center Hospital East30